Phage-display VHH antibody Screening Service to Develop In Vivo Gene Therapy
Closed Pre-Solicitation Posted
- Solicitation number
- 75N92024Q1050
- Agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
- More information
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services, National Heart Lung and Blood Institute, is seeking a phage-display VHH antibody screening service to develop in vivo gene therapy. The objective is to procure a service that can provide this screening capability. Key contract requirements include demonstrating expertise in phage-display VHH antibody screening and in vivo gene therapy development. The evaluation criteria will likely focus on the offeror's technical capabilities, experience, and past performance. The pre-solicitation notice was posted on July 17, 2024, with responses due by July 24, 2024.
This opportunity is not set aside for any specific socioeconomic program. No potential incumbents or current contractors are named. The pre-solicitation notice does not provide any information about award values or budget ranges. Additionally, the notice does not specify the quantity of goods or timeline for services.
Notice text
Phage-display VHH antibody Screening Service to Develop In Vivo Gene Therapy
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| AJ12--Development/Production - Kidney GEC-Specific AAV Vector | Veterans Integrated Service Network 4 | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity